• Find a Treatment Center
  • Investor Relations
  • Contact Us
  • About Us
    • Our Mission
    • Our Story
    • Therapeutic Areas
    • Leadership
    • Kite Locations
  • Cell Therapy
    • Our Cell Therapy Technology
    • Our Therapies
    • Pipeline
    • Trials & Expanded Access
    • Clinical Trial Diversity
    • External Research Program (ERP)
  • Patient Resources
    • Patient Stories
    • Our Authorized Treatment Centers
    • Kite Konnect
  • Newsroom
    • Newsroom
    • Press Releases
    • Company Statements
    • Media Kit
  • Careers
    • Careers
    • Veteran Careers
    • Early Talent Programs
    • Culture & Benefits
  • Utility
    • Investor Relations
    • Contact Us
    • Kite Konnect®
  • Contact Us
  • Find a Treatment Center
  • Investor Relations

Company Statements

Filter By Year

October 16, 2024

Kite Appoints Gallia Levy, MD, PhD, as Global Head of Clinical Development and Laura Alquist as Global Head of Technical Operations

October 3, 2024

Kite Receives U.S. FDA Regenerative Medicine Advanced Therapy Designation for the Evaluation of Yescarta® (axicabtagene ciloleucel) CAR T-cell Therapy as First-Line Treatment for Patients with High-Risk Large B-Cell Lymphoma

Filter By Year

Areas of Interest

  • Our Mission
  • Our Cell Therapy Technology
  • Pipeline
  • Careers at Kite

Information

  • Contact Us
  • Newsroom
  • Investors
  • KiteKonnect.com
  • Gilead.com
  • Sitemap

Legal

  • Privacy Policy
  • Consumer Health Data Privacy Policy
  • Terms and Conditions
  • Compliance Program
  • Social Media Guidelines

FOLLOW US

  • Icon X

© 2017-2025 Gilead Sciences, Inc. All rights reserved.

For Kite Medical Information, Clinical Trial Inquiries, Adverse Events, and Product Complaints please contact: (844) 454-KITE (5483), Monday–Friday 5 am–6 pm PT, Kite Medical Information: https://kitemedinfo.com